Related Experiment Video

Updated: Aug 11, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway

Niels W C J van de Donk1, Andries C Bloem, Ellen van der Spek

  • 1Dept of Hematology, University Medical Center Utrecht, Heidelberglaan 100, Huispost G03.647, 3584 CX Utrecht, the Netherlands.

Current Pharmaceutical Design
|February 4, 2006
PubMed

Insights

Targeting Bcl-2 and the mevalonate pathway can reverse drug resistance in multiple myeloma. Statins show promise in killing myeloma cells by inhibiting key anti-apoptotic proteins, paving the way for new treatments.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Drug resistance in hematological malignancies necessitates novel therapeutic strategies.
  • Bcl-2 protein overexpression in myeloma patients impacts chemosensitivity.
  • The mevalonate pathway is implicated in cellular survival and drug resistance.

Purpose of the Study:

  • To review Bcl-2 and mevalonate pathway as targets for overcoming drug resistance in multiple myeloma.
  • To explore the potential of statins in treating hematological malignancies.

Main Methods:

  • Review of in vitro and clinical studies on Bcl-2 targeting agents.
  • Analysis of statin mechanisms, including lovastatin's effect on geranylgeranylation and Mcl-1.
  • Examination of Phase 1 and 2 clinical trial data for Bcl-2 antisense oligonucleotides and simvastatin in myeloma patients.

Main Results:

  • Bcl-2 is a validated target due to its role in myeloma chemosensitivity.
  • Lovastatin induces apoptosis in myeloma and lymphoma cells by inhibiting geranylgeranylation and downregulating Mcl-1.
  • Clinical studies combining Bcl-2 targeting agents or high-dose simvastatin with chemotherapy show encouraging results in pre-treated myeloma patients.

Conclusions:

  • Targeting Bcl-2 and the mevalonate pathway offers a promising strategy for reversing drug resistance in multiple myeloma.
  • Statins, particularly lovastatin and simvastatin, demonstrate potential as anti-myeloma agents.
  • Clinical evidence supports the development of novel treatment strategies incorporating these targets for multiple myeloma therapy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...